Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has received a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $18.75.
Several research firms recently weighed in on MRNS. Mizuho reissued a “buy” rating and issued a $13.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, April 19th. ValuEngine raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, HC Wainwright began coverage on shares of Marinus Pharmaceuticals in a research note on Thursday, February 15th. They issued a “buy” rating and a $33.00 target price for the company.
Large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp bought a new position in shares of Marinus Pharmaceuticals in the third quarter valued at $128,000. FNY Partners Fund LP acquired a new stake in Marinus Pharmaceuticals during the 4th quarter valued at $183,000. Wells Fargo & Company MN acquired a new stake in Marinus Pharmaceuticals during the 4th quarter valued at $225,000. Goldman Sachs Group Inc. acquired a new stake in Marinus Pharmaceuticals during the 4th quarter valued at $305,000. Finally, Virtus Fund Advisers LLC acquired a new stake in Marinus Pharmaceuticals during the 4th quarter valued at $308,000. 63.67% of the stock is owned by institutional investors and hedge funds.
Shares of Marinus Pharmaceuticals traded up $0.01, hitting $4.81, during midday trading on Tuesday, Marketbeat Ratings reports. The stock had a trading volume of 254,254 shares, compared to its average volume of 983,895. Marinus Pharmaceuticals has a 12 month low of $1.13 and a 12 month high of $9.87.
Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Wednesday, May 2nd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.